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Abstract
Interpretation of variants present in complete genomes or exomes reveals
numerous sequence changes, only a fraction of which are likely to be
pathogenic. Mutations have been traditionally inferred from allele frequencies
and inheritance patterns in such data. Variants predicted to alter mRNA splicing
can be validated by manual inspection of transcriptome sequencing data,
however this approach is intractable for large datasets. These abnormal mRNA
splicing patterns are characterized by reads demonstrating either exon
skipping, cryptic splice site use, and high levels of intron inclusion, or
combinations of these properties. We present, Veridical, an in silico method for
the automatic validation of DNA sequencing variants that alter mRNA splicing.
Veridical performs statistically valid comparisons of the normalized read counts
of abnormal RNA species in mutant versus non-mutant tissues. This leverages
large numbers of control samples to corroborate the consequences of
predicted splicing variants in complete genomes and exomes.
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Introduction
DNA variant analysis of complete genome or exome data has typically relied on filtering of alleles according to population frequency
and alterations in coding of amino acids. Numerous variants of
unknown significance (VUS) in both coding and non-coding gene
regions cannot be categorized with these approaches. To address
these limitations, in silico methods that predict biological impact of
individual sequence variants on protein coding and gene expression
have been developed, which exhibit varying degrees of sensitivity
and specificity1. These approaches have generally not been capable
of objective, efficient variant analysis on a genome-scale.
Splicing variants, in particular, are known to be a significant cause
of human disease2–5 and indeed have even been hypothesized to
be the most frequent cause of hereditary disease6. Computational
identification of mRNA splicing mutations within DNA sequencing (DNA-Seq) data has been implemented to varying degrees of
sensitivity, with most software only evaluating conservation solely
at the intronic dinucleotides adjacent to the junction (i.e.7). Other
approaches are capable of detecting significant mutations at other
positions with constitutive, and in certain instances, cryptic, splice
sites5,8,9 which can result in aberrations in mRNA splicing. Presently,
only information theory-based mRNA splicing mutation analysis
has been implemented on a genome scale10. Splicing mutations can
abrogate recognition of natural, constitutive splice sites (inactivating mutation), weaken their binding affinity (leaky mutation), or
alter splicing regulatory protein binding sites that participate in
exon definition. The abnormal molecular phenotypes of these mutations comprise: (a) complete exon skipping, (b) reduced efficiency
of splicing, (c) failure to remove introns (also termed intron retention or intron inclusion), or (d) cryptic splice site activation, which
may define abnormal exon boundaries in transcripts using nonconstitutive, proximate sequences, extending or truncating the exon.
Some mutations may result in combinations of these molecular
phenotypes. Nevertheless, novel or strengthened cryptic sites can
be activated independently of any direct effect on the corresponding
natural splice site. The prevalence of these splicing events has been
determined by ourselves and others5,11–13. The diversity of possible
molecular phenotypes makes such aberrant splicing challenging to
corroborate at the scale required for complete genome (or exome)
analyses. This has motivated the development of statistically robust
algorithms and software to comprehensively validate the predicted
outcomes of splicing mutation analysis.
Putative splicing variants require empirical confirmation based on
expression studies from appropriate tissues carrying the mutation,
compared with control samples lacking the mutation. In mutations
identified from complete genome or exome sequences, corresponding transcriptome analysis based on RNA sequencing (RNA-Seq)
is performed to corroborate variants predicted to alter splicing.
Manually inspecting a large set of splicing variants of interest with
reference to the experimental samples’ RNA-Seq data in a program
like the Integrative Genomics Viewer (IGV)14, or simply performing
database searches to find existing evidence would be time-consuming
for large-scale analyses. Checking control samples would be required
to ensure that the variant is not a result of alternative splicing, but is
actually causally linked to the variant of interest. Manual inspection
of the number of control samples required for statistical power to

verify that each displays normal splicing would be laborious and
does not easily lend itself to statistical analyses. This may lead to
either missing contradictory evidence or to discarding a variant due
to the perceived observation of statistically insignificant altered
splicing within control samples. In addition, a list of putative splicing variants returned by variant prediction software can often be
extremely large. The validation of such a significant quantity of variants may not be feasible, for example, in certain types of cancer, in
instances where the genomic mutational load is high and only manual annotation is performed. We have therefore developed Veridical,
a software program that automatically searches all given experimental and control RNA-Seq data to validate DNA-derived splicing
variants. When adequate expression data are available at the locus
carrying the mutation, this approach reveals a comprehensive set
of genes exhibiting mRNA splicing defects in complete genomes
and exomes. Veridical and its associated software programs are
available at: www.veridical.org.

Methods
The program Veridical was developed to allow high-throughput
validation of predicted splicing mutations using RNA sequencing
data. Veridical requires at least three files to operate: a DNA variant file containing putative mRNA splicing mutations, a file listing of corresponding transcriptome (RNA-Seq) BAM files, and a
file annotating exome structure. A separate file listing RNA-Seq
BAM files for control samples (i.e. normal tissue) can also be provided. Here, we predict mutations in a set of breast tumours which
are validated with RNA-Seq data from the same individuals, with
RNA-Seq data from normal breast tissues as controls. However, in
principle, potential splicing mutations for any disease state with
available RNASeq data can be investigated. In each tumour, every
variant is analyzed by checking the informative sequencing reads
from the corresponding RNA-Seq experiment for non-constitutive
splice isoforms, and comparing these results with the same type of
data from all other tumour and normal samples that do not carry the
variant in their exomes.
Veridical concomitantly evaluates control samples, providing for
an unbiased assessment of splicing variants of potentially diverse
phenotypic consequences. Note that control samples include all
non-variant containing files, as well any normal samples provided.
Maximizing the set of control samples, while computationally
more expensive, increases the statistical robustness of the results
obtained.
For each variant, Veridical directly analyzes sequence reads aligned
to the exons and introns that are predicted to be affected by the
genomic variant. We elected to avoid indirect measures of exon
skipping, such as loss of heterozygosity in the transcript, because
of the possibility of confusion with other molecular etiologies (i.e.
deletion or gene conversion), unrelated to the splicing mutations.
The nearest natural site is found using the exome annotation file
provided, based upon the directionality of the variant, as defined
within Table 1. The genomic coordinates of the neighboring exon
boundaries are then found and the program proceeds, iterating over
all known transcript variants for the given gene. A diagram of this
procedure is provided in Figure 1. The variant location, C, is specifically referring to the, variant-induced, location of the predicted
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Table 1. Definitions used within Veridical to determine the
direction in which reads are checked. A and B represent natural
site positions, defined in Figure 1(b).
Pertinent Splice Site
A

B

Strand

Direction

Exonic

Donorα

+

→

Exonic

Donor

-

←

Intronic

Acceptorβ

+

←

Intronic

Acceptor

-

→

α

α

β

– 5′ splice site

β

– 3′ splice site

(A) All reads overlapping or between D or E are extracted
from the BAM files (D > E
swap D and E ).

(B) Veridical searches for validating reads between A and
B (B site left
of A
B
D. B site right
) of A
B E).

(C) An example of a continous read. The read start coordinate is denoted by S and its end coordinate by E.

(D) An example of a discontinous read. The start and end
coordinates of the read’s two portions are denoted by (s1,e1)
and (s2,e2).
Figure 1. A diagram portraying the definitions used within Veridical
to specify genic variant position and read coordinates. We employ
the same conventions as IGV14. Blue lines denote genes, wherein
thick lines represent exons and thin lines represent introns. Grey
lines denote reads, wherein thick lines denote a read mapping to
some particular location in the genome and thin lines represent
connecting segments of reads that are split across spliced-in
regions (i.e. exons or included introns).

mRNA splice site, which is often proximate to, but distinct from the
coordinate of the actual genomic mutation itself.
The program uses the BamTools API15 to iterate over all of the reads
within a given genomic region across experimental and control samples. Individual reads are then assessed for their corroborating value

towards the analysis of the variant being processed, as outlined in the flowchart in Figure 2. Validating reads are based on
whether they alter either the location of the splice junction (i.e.
junction-spanning) or the abundance of the transcript, particularly in intronic regions (i.e. read-abundance). Junction-spanning reads contain DNA sequences from two adjacent exons or
are reads that extend into the intron. These reads directly show
whether the intronic sequence is removed or retained by the
spliceosome, respectively. Read-abundance validated reads are
based upon sequences predicted to be found in the mutated transcript in comparison with sequences that are expected to be excised from the mature transcript in the absence of a mutation.
Both types of reads can be used to validate cryptic splicing, exon
skipping, or intron inclusion. A read is only said to corroborate
cryptic splicing if and only if the variant under consideration is
expected to activate cryptic splicing. Junction-spanning, cryptic
splicing reads are those in which a read is exactly split from the
cryptic splice site to the adjacent exon junction. For read-abundance
cryptic splicing, we define the concept of a read fraction, which
is the ratio of the number of reads corroborating the cryptically
spliced isoform and the number of reads that do not support the
use of the cryptic splice site (i.e. non-cryptic corroborating) in the
same genomic region of a sample. Cryptic corroborating reads are
those which occur within the expected region where cryptic splicing occurs (i.e. spliced-in regions). This region is bounded by the
variant splice site location and the adjacent (direction dependent) splice junction. Non-cryptic corroborating reads, which we
also term “anti-cryptic” reads, are those that do not lie within this
region, but would still be retained within the portion that would be
excised, had cryptic splicing occurred. To identify instances of exon
skipping, Veridical only employs junction-spanning reads. A read
is considered to corroborate exon skipping if the connecting read
segments are split such that it connects two exon boundaries, skipping an exon in between. A read is considered to corroborate intron
inclusion when the read is continuous and either overlaps with the
intron-exon boundary (and is then said to be junction-spanning) or
if the read is within an intron (and is then said to be based upon
read-abundance).
We proceed to formalize the above descriptions as follows. A given
read is denoted by r, with start and end coordinates (rs, re), if the read
is continuous, as diagrammed within Figure 1(c), or otherwise, with
start and end coordinate pairs, (rs , re ) and (rs , re ), as diagrammed
1
1
2
2
within Figure 1(d). Let ℓ be the length of the read. The set ζ denotes
the totality of validating reads. The criterion for r ∈ ζ is detailed
below. It is important to note that validating reads are necessary
but not sufficient to validate a variant. Sufficiency is achieved only
if the number of validating reads is statistically significant relative
to those present in control samples. ζ itself is partitioned into three
sets: ζc, ζe, and ζi for evidence of cryptic splicing, exon skipping,
and intron inclusion, respectively. We allow partitions to be empty.
Let S denote the relevant splice junctions as defined by Figure 1 and
Table 1. Without loss of generality, we consider only the red (i.e.
direction is right) set of labels within Figure 1(b). Then the (splice
consequence) partitions of ζ are given by:
r ∈ ζc ⇔ variant is cryptic ∧ rs – re = C – S ∨ (rs > A ∧ re < S)
2

1

r ∉ ζc ∧ variant is cryptic ∧ ¬ ( rs – re = C – S) ⇒ r ∈ anticryptic
2

r ∈ ζe ⇔ (re = A ∧ rs = B)
1

1

2

Page 4 of 23

F1000Research 2014, 3:8 Last updated: 18 MAR 2014

Figure 2. The algorithm employed by Veridical to validate variants. Refer to Table 1 for definitions concerning direction and Figure 1 for
variable definitions.
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r ∈ ζi ⇔ (A ∈ [rs, re] ∨ B ∈ [rs, re]) ∨ [(A ∉ [rs, re] ∧ B ∉ [rs, re])
∧ (rs < A – ℓ ∧ re > B ∧ r ∉ (A, B))]

N

µ=

We separately partition ζ by its evidence type, the set of junctionspanning reads, δ and read-abundance reads, α, as follows:
r ∈ δ ⇔ (A ∈ [rs, re] ∨ B ∈ [rs, re]) ∨ [r ∈ ζc ∧ rs – re = C – S].
2
1
r∈α⇔r∉δ

Once all validating reads are tallied for both the experimental and
control samples, a p-value is computed. This is determined by computing a z-score upon Yeo-Johnson (YJ)16 transformed data. This
transformation, shown in Equation 1, ensures that the data is sufficiently normally distributed to be amenable to parametric testing.

 ( x + 1)λ − 1

λ

log( x + 1)
ψ ( x, λ ) = 
2−λ
− (− x + 1) − 1

2−λ
−
−
log(
x + 1)


if x ≥ 0 ∧ λ ≠ 0
if x ≥ 0 ∧ λ = 0

(1)

if x < 0 ∧ λ ≠ 2
if x < 0 ∧ λ = 2

The transform is similar to the Box-Cox power transformation, but
obviates the requirement of inputting strictly positive values and
has more desirable statistical properties. Furthermore, this transformation allowed us to avoid the use of non-parametric testing, which
has its own pitfalls regarding assumptions of the underlying data
1
distribution17. We selected λ = –2, because Veridical’s untransformed
output is skewed left, due to their being, in general, less validating
reads in control samples and the fact that there are, by design, vastly
more control samples than experimental samples. We found that
this value for λ generally made the distribution much more normal.
A comparison of the distributions of untransformed and transformed data is provided in Figure S1. We were not concerned
about small departures from normality as a z-test with a large
number of samples is robust to such deviations18. It is important
to realize, therefore, that the p-values given by Veridical are much
more robust when the program is provided with a large number of
samples.
Thus, we can compute the p-value of the pairwise unions of the two
sets of partitions of ζ, except the irrelevant ζe ∪ α = ∅. We only
provide p-values for these pairwise unions and do not attempt to
provide p-values for the partitions for the different consequences
of the mutations on splicing. While such values would be useful,
we do not currently have a robust means to compute them. Our
previous work provides guidance on interpretation of splicing mutation outcomes3–5,10. Thus for ζx ∈ {ζc, ζe, ζi}, let ΦZ(z) represent the
cumulative distribution function of the one-sided (right-tailed —
i.e. P[X > x]) standard normal distribution. Let N represent the total
number of samples and let V represent the set of all ζx validations,
across all samples. Then:

z=

∑V
j =1

j

N
|ζ x | −µ
σ

σ =

1
N

N

∑ (V
j =1

j

− V )2

1
p = Φ (ψ ( z , ))
2

The program outputs two tables, along with summaries thereof.
The first table lists all validated read counts across all categories
for experimental samples, while the second table does the same for
the control samples. P-values are shown in parentheses within the
experimental table, which refer to the column-dependent (i.e. the
category is given in the column header) p-value for that category
with respect to that same category in control samples. The program
produces three files: a log file containing all details regarding validated variants, an output file with the programs progress reports and
summaries, and a filtered validated variant file. The filtered file contains all validated variants of statistical significance (set as p < 0.05, by
default), defined as variants with one or more validating read categories which achieve statistical significance in a relevant category
(i.e. a cryptic variant for which p = 0.04 in the junction-spanning
cryptic column would meet this criteria).
We elected to use RefSeq19 genes for the exome annotation, as opposed to, the more permissive exome annotation sets, UCSC Known
Genes20 or Ensembl21. The large number of transcript variants within
Ensembl, in particular, caused many spurious intron inclusion validation events. This occurred because reads were found to be intronic
in many cases, when in actuality they were exonic with respect to
the more common transcript variant. In addition, the inclusion of the
large number of rare transcripts in Ensembl significantly increased
program runtime and made validation events much more challenging
to interpret unequivocally. The use of RefSeq, which is a conservative annotation of the human exome, resolves these issues.
We also provide an R program22 which produces publication quality
histograms displaying embedded Q-Q plots and p-values, to evaluate
for normality of the read distribution and statistical significance,
respectively. The R program performs the YJ transformation as
implemented in the car package23. The histograms generated by
the program use the Freedman-Draconis24 rule for break determination, and the Q-Q plots use algorithm Type 8 for their quantile
function, as recommended by Hyndman and Fan25. Lastly, a Perl
program was implemented to automatically retrieve and correctly
format an exome annotation file from the UCSC database20 for use
in Veridical. All data uses hg19/GRCh37, however when new versions of the genome become available, this program can be used to
update the annotation file.

Results
Veridical validates predicted mRNA splicing mutations using highthroughput RNA sequencing data. The performance of the software
is affected by the number of predicted splicing mutations, the number of abnormal samples containing mutations and control samples
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and the corresponding RNA-Seq data for each type of sample.
Veridical has the ability to analyze approximately 3000 variants in
approximately 4 hours assuming an input of 100 BAM files of RNASeq data. The relationship between time and numbers of BAM files
and variants are plotted in Figure 3 for a 2.27 GHz processor. Veridical uses memory in linear proportion to the number and size of the
input BAM files. In our tests, using RNA-Seq BAM files with an
average size of approximately 6 GB, Veridical used approximately
0.7 GB for ten files to 1 GB for 100 files. Currently, splicing consequences that are reported include intron inclusion, exon skipping,
and cryptic splicing, which are validated through junction-spanning
reads, or based on read-abundance in the region circumscribing the
variant (see Methods for details). For example, a cryptic splicing
junction-spanning read will show that the mRNA contains a truncated or extended exon at the predicted location, which is directly
attached to the sequence of the corresponding adjacent exon. For
mutations that alter read-abundance, each read within the genomic
location assessed (i.e. intron for intron inclusion) is counted for the
variant-containing samples and then compared with the number of
reads in the control files. For each input variant, Veridical outputs
the number of validating reads (i.e. RNA-Seq reads which corroborate the predicted splicing consequence) for a given splice consequence within the variant-containing tumour samples and within
control samples (i.e. non-variant containing tumour samples and
normal samples). The program provides read counts for the different
categories for all experimental and control samples as tab-delimited
tables, along with the relevant p-values, indicating the statistical
probability that the predicted mutation exhibits a normal expression pattern.
We demonstrate how Veridical and its associated R program are
used to validate predicted splicing mutations in somatic breast
cancer. Each example depicts a particular variant-induced splicing
consequence, analyzed by Veridical, with its corresponding significance level. The relevant primary RNA-Seq data are displayed in

(A)

IGV, along with histograms and Q-Q plots showing the read distributions for each example. The source data are obtained from
controlled-access breast carcinoma data from The Cancer Genome
Atlas (TCGA)28. Tumour-normal matched DNA sequencing data
from the TCGA consortium was used to predict a set of splicing
mutations, and a subset of corresponding RNA sequencing data
was analyzed to confirm these predictions with Veridical. The following examples demonstrate the utility of Veridical to identify
potentially pathogenic mutations from a much larger subset of predicted variants.

Input, output, and explanatory files for Veridical
5 Data Files
http://dx.doi.org/10.6084/m9.figshare.894971

Leaky mutations are those variants that reduce, but not abolish, the
spliceosome’s ability to recognize the intron/exon boundary3. This
can lead to the mis-splicing (intron inclusion and/or exon skipping)
of many but not all transcripts. An example of a predicted leaky
mutation (chr5:162905690 G>T) in the HMMR gene in which both
junction-spanning exon skipping (p < 0.01) and read-abundancebased intron inclusion (p = 0.04) are observed is provided within
Figure 4. We predict this mutation to be leaky because its final Ri
exceeds 1.6 bits — the minimal individual information required
to recognize a splice site and produce correctly spliced mRNA4.
Indeed, the natural site, while weakened by 2.16 bits, remains
strong — 10.67 bits. This prediction is validated by the variantcontaining sample’s RNA-Seq data (Figure 4), in which both exon
skipping (5 reads) and intron inclusion (14 reads) are observed,
along with 70 reads portraying wild-type splicing. Only a single
normally spliced read contains the G→T mutation. These results
are consistent with an imbalance of expression of the two alleles,

(B)
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Time (min)
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Number of BAM Files
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0
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Number of Variants

Figure 3. Profiling data for Veridical runtime. Tests were conducted upon an Intel Xeon @2.27 GHz. Visualizations were generated with R22
using Lattice26 and Effects27. A surface plot of time vs. numbers of BAM files and variants is provided in (A). Effect plots are given in (B) and
demonstrate the effects of the numbers of BAM files and variants upon runtime. The effect plots were generated using a linear regression
model (R 2 = 0.7525).
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(A)

(B)

Figure 4. IGV images depicting a predicted leaky mutation (chr5:162905690 G>T) within the natural acceptor site of exon 12 (162905689–
162905806) of HMMR. This gene has four transcript variants and the given exon number pertains to isoforms a and b (reference sequences
NM_001142556 and NM_012484). RNA-Seq reads are shown in the centre panel. The bottom blue track depicts RefSeq genes, wherein
each blue rectangle denotes an exon and blue connecting lines denote introns. In the middle panel, each rectangle (grey by default) denotes
an aligned read, while thin lines are segments of reads split across exons. Red and blue coloured rectangles in the middle panel denote
aligned reads of inserts that are larger or smaller than expected, respectively. (A) depicts a genomic region of chromosome 5: 162902054–
162909787. The variant occurs in the middle exon. Intron inclusion can be seen in this image, represented by the reads between the first and
middle exon (since the direction is right, as described within Table 1). These 14 reads are read-abundance-based, since they do not span
the intron-exon junction. (B) depicts a closer view of the region shown in (A) — 162905660–162905719. The dotted vertical black lines are
centred upon the first base of the variant-containing exon. The thin lines in the middle panel that span the entire exon fragment are evidence
of exon skipping. These 5 reads are split across the exon before and after the variant-containing exon, as seen in (A).

6

Sample Quantiles

2

4

60

0

40

Frequency

−3

−2

−1

0

1

2

3

20

Standard Normal Quantiles of YJ Transformed Data

0

Variants that inactivate splice sites have negative final Ri values3
with only rare exceptions4, indicating that splice site recognition
is essentially abolished in these cases. We present the analysis of
two inactivating mutations within the PTEN and TMTC2 genes
from different tumour exomes, namely: chr10:89711873 A>G
and chr12:83359523 G>A, respectively. The PTEN variant displays junction-spanning exon skipping events (p < 0.01), while the
TMTC2 gene portrays both junction-spanning and read-abundancebased intron inclusion (both splicing consequences with p < 0.01).
In addition, all intron inclusion reads in the experimental sample
contain the mutation itself, while only one such read exists across
all control samples analyzed (p < 0.01). The PTEN variant contains numerous exon skipping reads (32 versus an average of 2.466
such reads per control sample). The TMTC2 variant contains many
junction-spanning intron inclusion reads with the G→A mutation
(all of its junction-spanning intron inclusion reads: 22 versus an
average of 0.002 such reads per control sample). IGV screenshots
for these variants are provided within Figure 6. This figure also
shows an example of junction-spanning cryptic splice site activated
by the mutation (chr1:985377 C>T) within the AGRN gene. The
concordance between the splicing outcomes generated by these
mutations and the Veridical results indicates that the proposed
method detects both mutations that inactivate splice sites and cryptic splice site activation.

8

as expected for a leaky variant. Figure 5 shows that for the distribution of read-abundance-based intron inclusion is statistically
significant (p = 0.04).

0

5

10

15

20

25

30

Read−Abundance Total Intron Inclusion
Figure 5. Histogram of read-abundance-based intron inclusion
with embedded Q-Q plots of the predicted leaky mutation
(chr5:162905690 G>T) within HMMR, as shown in Figure 4. The
arrowhead denotes the number of reads (14 in this case) in the
variant-containing file which is more than observed in the control
samples (p = 0.04).
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(A)

(B)

(C)

(D)

Figure 6. (A) depicts an inactivating mutation (chr10:89711873 A>G) within the natural acceptor site of exon 6 (89711874–89712016)
of PTEN. The dotted vertical black line denotes the location of the relevant splice site. The region displayed is 89711004–89712744 on
chromosome 10. Many of the 32 exon skipping reads are evident, typified by the thin lines in the middle panel that span the entire exon.
There is also a significant amount of read-abundance-based intron inclusion, shown by the reads to the left of the dotted vertical line. Exon
skipping was statistically significant (p < 0.01), while read-abundance-based intron inclusion was not (p = 0.53). Panels (B) and (C) depict
an inactivating mutation (chr12:83359523 G>A) within the natural donor site of exon 6 (83359338–83359523) of TMTC2. (B) depicts a closer
view (83359501–83359544) of the region shown in (C) and only shows exon 6. Some of the 22 junction-spanning intron inclusion reads can
be seen. In this case, all of these reads contain the mutation, shown by the green adenine base in each read, between the two vertical dotted
lines. (C) depicts a genomic region of chromosome 12: 83359221–83360885, TMTC2 exons 6–7. The variant occurs in the left exon. 65 readabundance-based intron inclusion can be seen in this image, represented by the reads between the two exons. Panel (D) depicts a mutation
(chr1:985377 C>T) causing a cryptic donor to be activated within exon 27 (the second from left, 985282–985417) of AGRN. The region
displayed is 984876–985876 on chromosome 1 (exons 26–29 are visible). Some of the 34 cryptic (junction-spanning) reads are portrayed.
The dotted black vertical line denotes the cryptic splice site, at which cryptic reads end. Refer to the caption of Figure 4 for IGV graphical
element descriptions.

Recurrent genetic mutations in some oncogenes have been reported
among tumours within the same, or different, tissues of origin.
Common recurrent mutations present in multiple abnormal samples are recognized by Veridical. This avoids including a variantcontaining sample among the control group, and outputs the results of
all of the variant-containing samples. A relevant example is shown

in Figure 7. The mutation (chr1:46726876 G>T) causes activation of a cryptic splice site within RAD54L in multiple tumours.
Upon computation of the p-values for each of the variant-containing
tumours, relative to all non-variant containing tumours and normal
controls, not all variant-containing tumours displayed splicing abnormalities at statistically significant levels. Of the six variant-containing
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Figure 7. IGV images and their corresponding histograms with embedded Q-Q plots depicting all six variant containing files with a mutation
(chr1:46726876 G>T) which, in some cases, causes a cryptic donor to be activated within the intron between exons 7 and 8 of RAD54L.
This results in the extension of the downstream natural donor (the 5´ end of exon 8). This gene has two transcript variants and the given exon
numbers pertain to isoform a (reference sequence NM_003579). Only samples IV and V have statistically significant intron inclusion relative
to controls. read-abundance-based intron inclusion can be seen in (A), between the two exons. The region displayed is on chromosome 1:
46726639–46726976. (B) depicts the corresponding histogram for the 15 read-abundance-based intron inclusion reads (p = 0.05) that are
present in sample IV. The intron-exon boundary on the right is the downstream natural donor. (C) typifies some of the 13 junction-spanning
intron inclusion reads that are a direct result of the intronic cryptic site’s activation. In these instances, reads extending past the intron-exon
boundary are being spliced at the cryptic site, instead of the natural donor. In particular, samples IV and V both have a statistically significant
numbers of such reads, 7 (p = 0.01) and 5 (p = 0.04), respectively. This is further typified by the corresponding histogram in (D). (C) focuses
upon exon 8 from (A) and displays the genomic positions 46726908–46726957. Refer to the caption of Figure 4 for IGV graphical element
descriptions. In the histograms, arrowheads denote numbers of reads in the variant-containing files. The bottom of the plots provide p-values
for each respective arrowhead. Statistically significant p-values and their corresponding arrowheads are denoted in red.
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tumours, two had significant levels of junction-spanning intron
inclusion, and one showed statistically significant read-abundancebased intron inclusion. Details for all of the aforementioned variants, including a summary of read counts pertaining to each relevant
splicing consequence, for experimental versus control samples, are
provided in Table 2.

Discussion
We have implemented Veridical, a software program that automates
confirmation of mRNA splicing mutations by comparing sequence
read-mapped expression data from samples containing variants that
are predicted to cause defective splicing with control samples lacking these mutations. The program objectively evaluates each mutation with statistical tests that determine the likelihood of and exclude
normal splicing. To our knowledge, no other software currently
validates splicing mutations with RNA-Seq data on a genome-wide
scale, although many applications can accurately detect conventional alternative splice isoforms (i.e.29). Veridical is intended for
use with large data sets derived from many samples, each containing several hundred variants that have been previously prioritized as
likely splicing mutations, regardless of how the candidate mutations
are selected. It is not practical to analyze all variants present in an
exome or genome, rather only a filtered subset, due to the extensive
computations required for statistical validation. As such, Veridical
is a key component of an end-to-end, hypothesis-based, splicing
mutation analysis framework that also includes the Shannon splicing mutation pipeline10 and the Automated Splice Site Analysis and
Exon Definition server5.
There is a trade-off between lengthy run-times and statistical robustness of Veridical, especially when there are either a large number of
variants or a large number of RNA-Seq files. As with most statistical
methods, those employed here are not amenable to small sample
sets, but become quite powerful when a large number of controls
are employed. In order to ensure that mutations can be validated,
we recommend an excess of control transcriptome data relative to
those from samples containing mutations (> 5 : 1), regardless of the
computational expense. We do not recommend the use of a single
control to corroborate a sample containing a putative mutation. Not
surprisingly, we have found that junction-spanning reads have the
greatest value for corroborating cryptic splicing and exon skipping.
Even a single such read is almost always sufficient to merit the validation a variant, provided that sufficient control samples are used.
For intron inclusion, both junction-spanning and read-abundancebased reads are useful and a variant can readily be validated with
either, provided that the variant-containing experimental sample(s)
show a statistically significant increase in the presence of either
form of intron inclusion corroborating reads.
Veridical is able to automatically process variants from multiple
different experimental samples, and can group the variant information if any given mutation is present in more than one sample. The
use of a large sample size allows for robust statistical analyses to be
performed, which aid significantly in the interpretation of results.
The main utility of Veridical is to filter through large data sets of
predicted splicing mutations to prioritize the variants. This helps
to predict which variants will have a deleterious effect upon the

protein product. Veridical is able to avoid reporting splicing changes
that are naturally occurring through checking all variant-containing
and non-containing control samples for the predicted splicing consequence. In addition, running multiple tumour samples at once
allows for manual inspection to discover samples that contained the
alternative splicing pattern, and consequently, permits the identification of DNA mutations in the same location which went undetected during genome sequencing.
The statistical power of Veridical is dependent upon the quality of the
RNA-Seq data used to validate putative variants. In particular, a lack
of sufficient coverage at a particular locus will cause Veridical to be
unable to report any significant results. A coverage of at least 20 reads
should be sufficient. This estimate is based upon alternative splicing
analyses in which this threshold was found to imply concordance
with microarray and RT-PCR measurements30–33. There are many
potential legitimate reasons why a mutation may not be validated:
(a) nonsense-mediated decay may result in a loss of expression of
the entire transcript, (b) the gene itself may have multiple paralogs and reads may not be unambiguously mapped, (c) other nonsplicing mutations could account for a loss of expression, and (d)
confounding natural alternative splicing isoforms may result in a
loss of statistical significance during read mapping of the control
samples. The prevalence of loci with insufficient data is dependent
upon the coverage of the sequencing technology used. As sequencing technologies improve, the proportion of validated mutations is
expected to increase. Such an increase would mirror that observed
for the prevalence of alternative splicing events34. It is important to
note that acceptance of the null hypothesis, due to an absence of
evidence required to disprove it, does not imply that the underlying
prediction of a mutation at a particular locus is incorrect, but merely
that the current empirical methods employed were insufficient to
corroborate it.
While there is considerable prior evidence for splicing mutations
that alter natural and cryptic splice site recognition, we were somewhat surprised at the apparent high frequency of statistically significant intron inclusion revealed by Veridical. In fact, evidence
indicates that a significant portion of the genome is transcribed34,
and it is estimated that 95% of known genes are alternatively
spliced30. Defective mRNA splicing can lead to multiple alternative transcripts including those with retained introns, cassette
exons, alternate promoters/terminators, extended or truncated
exons, and reduced exons35. In breast cancer, exon skipping and
intron retention were observed to be the most common form of
alternative splicing in triple negative, non-triple negative, and
HER2 positive breast cancer36. In normal tissue, intron retention
and exon skipping has been predicted to affect 2572 exons in 2127
genes and 50 633 exons in 12 797 genes, respectively37. In addition,
previous studies suggest that the order of intron removal can influence the final mRNA transcript composition of exons and introns38.
Intron inclusion observed in normal tissue may result from those
introns that are removed from the transcript at the end of mRNA
splicing. Given that these splicing events are relatively common
in normal tissues, it becomes all the more important to distinguish
expression patterns that are clearly due to the effects of splicing
mutations — one of the guiding principles of the Veridical method.
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Table 2. Examples of variants validated by Veridical. Header abbreviations Chr, Cv, Cs, #, SC, and ET, denote chromosome, variant coordinate, splice site coordinate,
sample number (where applicable), splicing consequence, and evidence type, respectively. Headers containing R with some subscript denote numbers of validated
reads for the specified variant’s splicing consequence(s) and evidence type(s). RE denotes reads within variant-containing tumour samples. RT and RN denote control samples,
for tumours and normal cells, respectively. Rμ is the per sample mean of RT and RN. Splicing consequences: CS denotes cryptic splicing, ES denotes exon skipping, and II
denotes intron inclusion. Evidence types: JS denotes junction-spanning and RA denotes read-abundance.
Gene

Chr

Cv

HMMR

chr5

162905690 162905689 G/T

Cs

Variant Type
Leaky

Initial Ri Final Ri ΔRi
12.83

10.67

#

-2.16

SC

ET

p-value

RE

RT

RN

Rμ

Figure

ES

JS

< 0.01

5

11

0

0.020

[4],[5]

II

RA

0.04

14

2133

103

4.051

PTEN

chr10 89711873

89711874

A/G

Inactivating 12.09

-2.62

-14.71

ES

JS

< 0.01

32

975

386

2.466

[6(A)]

TMTC2

chr12 83359523

83359524

G/A

Inactivating 1.74

-1.27

-3.01

II

JS

< 0.01

22

2241

383

4.754

[6(B)]

II

JSwM

< 0.01

22

0

1

0.002

II

RA

< 0.01

65

7293

1395

15.739

[6(C)]

CS

JS

< 0.01

34

97

23

0.217

[6(D)]

II

JS

N/A

0

645

58

1.274

[7]

II

RA

0.54

3

2171

290

4.458

II

JS

0.51

1

645

58

1.274

II

RA

0.33

6

2171

290

4.458

II

JS

N/A

0

645

58

1.274

II

RA

0.33

6

2171

290

4.458

II

JS

0.01

7

645

58

1.274

II

RA

0.05

15

2171

290

4.458

II

JS

0.04

5

645

58

1.274

II

RA

N/A

0

2171

290

4.458

II

JS

N/A

0

645

58

1.274

II

RA

N/A

0

2171

290

4.458

AGRN

chr1

RAD54L chr1

985377

985376

C/T

Cryptic

-2.24

4.79

7.03

46726876

46726895

G/T

Cryptic

13.4

14.84

1.44

I
II
III
IV
V
VI
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Veridical is an important analytical resource for unsupervised, thorough validation of splicing mutations through the use of companion RNA-Seq data from the same samples. The approach will be
broadly applicable for many types of genetic abnormalities, and
should reveal numerous, previously unrecognized, mRNA splicing
mutations in exome and complete genome sequences.

Data availability
figshare: Input, output, and explanatory files for Veridical, http://
dx.doi.org/10.6084/m9.figshare.89497139.
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Supplementary materials
Veridical variant input format
This input format most easily accepts formatted output from the
Shannon Pipeline. In particular, all variants of interest should be

concatenated into a single file. Once a, tab-delimited, concatenated
file has been generated, it can easily be formatted correctly by using
FilterShannonPipelineResults.pl. One can also manually ensure the following: the header line has no quotation marks or
special characters, empty columns have been replaced by a period (.)
and each variant line contains only a single gene (comma-delimited
gene lists must be split such that there is only one gene per line). If
one wishes Veridical to consider variants pertaining to more than
one experimental sample, a comma-delimited list of experimental
samples, in the form of BAM file names, must be provided as the
key column. The key column must always contain at least one file
name that is present as the base name of one of the files listed in the
BAM file list that must be passed to Veridical.
Alternatively, one can prepare the input format as follows. The header
must contain at least the following, case-insensitive, values to which
the file’s columns must adhere to: chromosome, splice&coordinate,
strand, type, gene, location, location_type, heterozygosity, variant,
input, key. The column headers need only contain the given text (i.e.
a column labeled gene_name would be sufficient to satisfy the
above requirement for a “gene” column). Column headers with ampersands (&) denote that all words joined by this symbol must be present for that column (i.e. Splice_site_coordinate satisfies
the “splice&coordinate” requirement). The order of the columns is
immaterial. The input column can contain any identifier for the variant and need not be unique. The location column specifies if the
site is natural or cryptic. For Veridical, all that matters is that cryptic
variants contain the word “cryptic” as part of their value in this column and that non-cryptic variants do not. The location_type
column is only used for cryptic variants and specifies if the variant
is intronic or exonic. It is not currently used by the program. This
column must be present but can always be set to null (i.e.).
A few rows from a sample variant file is provided below (text
wrapped for readability):
Chromosome Splice_site_coordinate Strand
Ri-initial Ri-final ∆Ri Type Gene_Name
Location Location_Type Loc._Rel._to_exon
Dist._from_nearest_nat._site
Loc._of_nearest_nat._site
Ri_of_nearest_nat Cryptic_Ri_rel._nat.
rsID Average_heterozygosity
Variant_coordinate Input_variant Input_ID
RNASeqDirectory_ID RNA_Seq_BAM_ID_KEY
chr10 89711874 + 12.09 -2.62 -14.71
ACCEPTOR PTEN NATURALSITE . . . . . . .
. 89711873 A/G ID1 dir file
chr10 89712017 + 5.18 -1.85 -7.03 DONOR
PTEN NATURALSITE . . . . . . . . 89712018
T/C ID1 dir file
chrX 9621719 + -4.78 2.25 7.03 DONOR
TBL1X CRYPTICSITE EXONIC . 11 9621730 2.24
GREATER . . 9621720 C/T ID1 dir file

Veridical exome annotation input format
This
input
format
can
be
generated
via
ConvertToExomeAnotation.pl. The file must be
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tab-delimited, excepting its header, which must be comma-delimited. It must have the following, case-insensitive, header columns,
to which its data must adhere: transcript, chromosome, exon chr
start, exon chr end, exon rank, gene. The column headers need only
contain the given text (i.e. a column labeled gene_name would
be sufficient to satisfy the above requirement for a “gene” column).
The order of the columns is immaterial.
A few rows from a sample exome annotation file is provided below
(text wrapped for readability):
Transcript ID,ID,ID,Chromosome Name,Strand,
Exon Chr Start,Exon Chr End,
Exon Rank in Transcript,Transcript Start,
Transcript End, Associated Gene Name
NM_213590 NM_213590 NM_213590 chr13 +
50571142 50571899 1 50571142 50592603
TRIM13
NM_213590 NM_213590 NM_213590 chr13 +
50586070 50592603 2 50571142 50592603
TRIM13
NM_198318 NM_198318 NM_198318 chr19 +
50180408 50180573 1 50180408 50191707
PRMT1

Veridical output
If a variant contains any validating reads, Veridical outputs the variant in question, along with some summary information and a table
specifying the numbers of each validating read type detected for
both the experimental and control samples. Within the output of
Veridical, the phrase: “Validated (x) variant n times” means that

the variant was validated mainly for splicing consequence x and
has n validating reads. The variant will only appear within the
*.filtered output file if the p-value for either junction-spanning
or read-abundance-based reads for splicing consequence x was statistically significant (defined, by default, as: p < 0.05). After the
variant being validated is provided, along with its primary predicted splicing consequence, the output is divided into two sections
with identical contents: one for the experimental sample(s) and
another for control samples. The summary enumerates the number of reads of each splicing consequence, partitioned by evidence
type (junction-spanning or read-abundance-based), and by sample
type (tumour or normal for control samples, and only tumour for
experimental samples). A table describing the number of each read
type for every file follows this summary. An example of this output, for the variant within RAD54L, as shown by Figure 7 and the
last portion of Table 2, is provided. While Veridical outputs this as
plain text, with the table in a tab-delimited format, we provide this
output as an Excel document with descriptions of the meaning of
each table heading, to clarify the presentation of the data. All input
and output files for the five variants presented are provided.
VeridicalOutExample.xls
contains
the
output
for the variant within RAD54L, along with descriptions of
the terms used and the output format. all.vin contains the
input variant file.
allTumoursBAMFileList.txt and
allNormalsBAMFileList.txt are the BAM file lists
for tumour and normal samples, respectively. all.vout contains the Veridical output. The exome file can be retrieved using
ConvertToExomeAnnotation.pl, available with the other
programs at: www.veridical.org. The BAM file lists contain the
TCGA file UUID, followed by a slash, followed by the file name.
The RNA-Seq data itself can be downloaded from TCGA at: https://
tcga-data.nci.nih.gov/tcga/.
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Figure S1. Histogram and embedded Q-Q plots portraying the difference between untransformed and Yeo-Johnson (YJ) transformed
data. The plots depict intron inclusion for the inactivating mutation (chr12:83359523 G>A) within TMTC2, as shown in Figure 6(B) and 6(C).
The arrowheads denote the number of reads in the variant-containing file, which is, in all cases, more than observed in the control samples
(p < 0.01). The figure legend for all panels is provided in (G), which shows that blue and red plot elements correspond to untransformed
data, while yellow and purple correspond to YJ transformed elements. Dotted lines in the Q-Q plots are lines passing through the first
and third quantiles for a normal reference distribution. (A), (C), and (E) show junction-spanning based reads, while (B), (D), and (F) show
read-abundance-based reads. (A)-(B) depict tumour sample distributions, (B)-(C) depict normal sample distributions, and (E)-(F) depict
combined tumour and normal sample distributions. This figure is demonstrative of the general trend we have observed. Only data from normal
samples resemble a Gaussian distribution and the YJ transformation greatly improves the Gaussian nature of all distributions.
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Approved: 18 March 2014
Referee Report: 18 March 2014
This paper from the Rogan group presents a methodology for validation of DNA sequencing variants that
alter mRNA splicing. While variants of the most conserved splice site nucleotides at the intron-exon
boundary can be predicted to cause splice defects with high reliability, it remains difficult to predict
whether variants deeper in the intron or those that potentially affect exonic splicing enhancers actually
cause splice defects. RNA-seq data, when coupled with variant data, potentially provide a means of
correlating variation data with observations of (mis-)splicing patterns.
The program fulfils an important need in the community, the results appear promising and will be of
special interest to groups performing RNA-seq analysis in medical settings. I have only some minor
suggestions that the authors may like to consider.

Suggestions:
1. The explanation of the methodology is relatively difficult to follow, and I wonder if it might not be
better to simplify Figures 1 and 2 for didactic sake. For instance, in Figure 1A, it is unclear where
the location of variant C is. Does the curved line mean that it could be anywhere in the middle
exon? Also, I assume that exons are being shown in blue and reads shown in gray?
Also, the legend text is overly complicated: D > E swap D and E. While aficionados of first order
logic will follow without problems, I would suggest that it would be better for didactic purposes to
delete this and to implicitly assume that D<E for the sake of this figure. Figure 1B is confusing at
this point in the manuscript because the motivation for switching the variable A,B, D, and E is not
yet clear. On the other hand, panel C and panel D are trivial and do not add anything. I would
suggest using Figure 1 to provide one concrete example one a simple level, and stating in the text
that the variables are to be switched if the candidate mutation is located on the other side of the
exon.
Also, the explanations of the method that are couched in first order logic-like notation are difficult to
follow, because it is not stated whether the variant C can precede the start of the read (in which
case C-S would be negative). The subscripts for r in turn have the subscript s1 but the variable S in
the formula does not.
Although in the end, I think I follow the overall method, the reader is forced to make arbitrary
assumptions in order to interpret the formulae being used to explain the method. A similar
comment pertains to the flow chart in Figure 2.

Therefore, I would suggest the authors take some pains to improve the clarity of the explanation of
F1000Research
Page 17 of 23

F1000Research 2014, 3:8 Last updated: 18 MAR 2014

Therefore, I would suggest the authors take some pains to improve the clarity of the explanation of
the method. I would suggest that they show one of two concrete examples and provide English
language specifications of the FOL-like formulae that describe the partitioning of reads.
2. I am a little unclear on the use of control samples vs experimental samples. Assuming the
experimental samples come from different individuals, what is the reason to assume that they will
have the same distribution of splice mutations? And given that one finds dozens of splice variants
in normal individuals, what exactly is meant by a control sample? Will control samples not also
have lots of splice mutations? How does the method deal with this? And if we are dealing with
cancer samples, why not user a paired control to detect cancer-specific mutations? In light of this,
the statement "Maximizing the set of control samples, while computationally more expensive,
increases the statistical robustness of the results obtained.", does not appear to be supported by
evidence presented in the manuscript.
3. It would be interesting to see a comparison of the distribution of Ri values and results of Veridical
analysis?
4. How does Veridical decide which sequence variant is causative if there are multiple variations
located in the vicinity of a given mis-spliced exon?
5. The mutation nomenclature chr1:985377 C>T should not have a space between the position and
the nucleotides.
6. It is unclear to me why a linear regression model was used to show the performance of the method.
The authors could provide timings from real runs.
7. It would be interesting to see a plot on the relationship of the p-values called by Veridical and the
sequencing depth covered. The authors state "In particular, a lack of sufficient coverage at a
particular locus will cause Veridical to be unable to report any significant results. A coverage of at
least 20 reads should be sufficient.", but they do not provide evidence for this assertion. This is an
important question given that low-expressed genes are thus likely to be systematically
under-represented in the results of Veridcal, and this should be commented on somewhere in the
paper.
8. It would be good if the authors provided Sanger validation of at least some of the mis-splicing
events reported in the paper.
9. The input format for Veridical is described as "This input format most easily accepts formatted
output from the Shannon Pipeline." Why not allow VCF files and filter them for potential splice
variants informatically prior to Veridcal analysis? It was unclear to me how the variants are to be
selected and whether Veridical can be easily used outside of the Shannon pipeline?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
Liliana Florea
McKusick-Nathans Institute of Human Genetics, Johns Hopkins University, Baltimore, MD, USA
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Approved with reservations: 07 March 2014
Referee Report: 07 March 2014
The authors describe a method and the associated software, Veridical, for assessing the effects on
pre-mRNA splicing of predicted splicing-affecting mutations. To do so the program compares splicing
effects, measured by the supporting read counts, in variant-containing (disease) samples against a
distribution derived from very large numbers of 'normals', either normal tissue from the same individual or
samples from healthy individuals.
The idea is ingenious and novel as applied to mutations affecting splicing, although not in general (see
VAAST [Yandell et al. 2011], which exploits the availability of large numbers of samples to identify likely
deleterious variants; it is also the premise for the HapMap and 1000 Genomes projects). The software is
fast and practical, being able to test thousands of variants in hundreds of samples within hours. This is the
first software of its kind, and if accurate it will be a very valuable resource for clinical genomics.
That being said, while the article provides proof-of-concept and clearly demonstrates the potential of the
tool with specific examples, there are several missing pieces that are needed to provide the readers with
a view of its overall performance and limitations and to help them use it effectively.
Major comments:
1. The article shows numerous positive examples, however there is no indication of the tool's
performance in general. The authors should include the results from running the tool on a full data
set, to give potential users an idea of the expected outcome.
Also, several other tools (e.g., MATS, Miso, SpliceTrap) have been developed for the related
problem of discovering alternative splicing events and comparing them among samples. MATS in
particular, allows differential splicing analyses with multiple replicates. Ideally the paper would
include a comparison with MATS on the data set analyzed; this comparison is informative even if
MATS is used with only a subset of the samples.
2. The method uses the YJ-transformed distribution of supporting read counts across the 'normals' to
determine a p-value for the variant, and thus judge its significance and impact on splicing. This is
an interesting concept that assumes that with large numbers of 'normals' sample and batch effects
will even out; hence, large numbers of samples are required to ensure accuracy. Since these are
absolute (non-normalized) counts, however, the method may not work if the variant sample is
obtained with a different method, e.g. by rRNA depletion of total RNA whereas most normal
samples would come from polyA+ libraries. The authors should clearly discuss this and other
possible limitations of their approach.
3. Related to the above, the authors mention on several occasions the difficulty in identifying intron
inclusion (II) events, in particular the large number of false positives. Indeed, IIs are generally
difficult to predict due to the presence of intronic reads ('noise') from unspliced RNA. The levels
can vary from sample to sample and across the genome, depending on the sample preparation,
gene expression level, splicing efficiency, etc. By comparing read counts exclusively among
samples and without taking into account the gene- or genome-level background, Veridical is likely
to produce many false positives.
In particular, the 14 supporting reads in the left intron on Figure 4 seem hardly sufficient to indicate
an II event, all the more as there is a larger number of reads in the neighboring intron (not predicted
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an II event, all the more as there is a larger number of reads in the neighboring intron (not predicted
to be II). The authors should provide other type of evidence for this event.
4. The mathematical formulas for the various classes of supporting reads and their locations (page 4,
continued on page 6) are hard to understand. It would greatly help the readers to include a figure
showing schematically the event and read location with respect to the introns and exons.
Minor comments:
1. As another reviewer pointed out, the software requires a registration to obtain a temporary license
for 30 days, after which the availability and terms of use are unclear. This mode of distribution is
not a problem, but the terms should be clearly stated in the manuscript. Also, this is a stand-alone
software and not a web tool as implied by the article.
2. The authors use the term 'cryptic' splice sites throughout the manuscript (I assume meaning
'aberrantly activated'), but some of the events discovered could be alternative exon ends. It would
be helpful to clarify in the context.
This is a potentially very powerful and useful tool. I gave the article an 'Approved with reservation'
because it is critical to include results in the aggregate to complement the showcased examples, as well
as to discuss its limitations. I will gladly change once these few issues are addressed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Competing Interests: No competing interests were disclosed.
Francesc Xavier Roca
Division of Molecular Genetics and Cell Biology, Nanyang Technological University, Singapore,
Singapore
Approved: 28 January 2014
Referee Report: 28 January 2014
This manuscript describes a new computational tool named Veridical, which detects mutant-allele specific
splicing changes from large RNAseq datasets. This outstanding tool appears very useful to screen the
wealth of transcriptomic data for effects in splicing due to mutations in disease samples, and I think that it
will potentially be of interest for many if not all such RNAseq-based studies. In addition, this could spur
further efforts to derive similar tools with improved efficiencies. Use of this method should help establish
the importance of aberrant splicing in disease as well as the effects of genomic mutations at the RNA
level. I only have two comments, that do not diminish my overall rating of this work as of high value:
1. I personally disagree with the widespread use of the word “validation” in the title, abstract and text.
Authors describe Veridical as a tool to “validate” DNA sequence variants that alter splicing. Indeed,
I think that this tool provides an “association” between the variants and splicing, but not a formal
proof of their connection. As the genomic and RNA samples usually come from different individuals
with many confounding variables, the possibility that the splicing changes arise from factors other
than the individual DNA mutations cannot be ruled out. In other words, changes in the levels of
trans-acting splicing factors could account in part or totally for the splicing changes across
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trans-acting splicing factors could account in part or totally for the splicing changes across
samples. The statistical tests properly conducted in Veridical are designed to minimize such
possibility but do not rule it out. In addition, the inherent noisy nature of RNAseq datasets also
prompts for caution in the conclusions. To me, the direct proof that a DNA mutation changes
splicing of its pre-mRNA can only be provided using minigenes and cell transfection (or in vitro
splicing), in which the substrate sequences and cellular context are under almost absolute control.
Indeed, the Veridical method is reminiscent of GWAS (Genome-Wide Association Studies), in
which the genotype in the DNA, wild-type or mutant, is associated to its phenotype, such as normal
versus disease (or other traits) in GWAS, or normal versus aberrant splicing in this study. Thus, for
me Veridical provides strong associations – but not validations – between DNA mutations and their
effects on splicing.
2. As mentioned briefly at the beginning of Discussion, Veridical has built-in prediction tools to
prioritize the mutations that are more likely to affect splicing, such as those mapping to splice sites.
Even if other sources and tools are cited, a more extensive explanation of these components of
Veridical would help the reader/user.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
Stefania Bortoluzzi
Department of Biology, University of Padova, Padova, Italy
Approved with reservations: 27 January 2014
Referee Report: 27 January 2014
The paper “Validation of predicted mRNA splicing mutations using high-throughput transcriptome data” by
Viner et al. presents Veridical, a new software for the interpretation and validation of genetic variants
identified by DNA sequencing that alter mRNA splicing, leveraging RNA-seq data. The method is based
on statistical comparisons of the normalized read counts of abnormally-spliced RNA species in mutant
versus non-mutant tissues.
Actually, the interpretation of genetic variants is a difficult and key issue in current research.
The integration of genomic and transcriptomic data, namely the use of RNA-seq-based transcriptome
characterization as a “molecular phenotype” of cells is useful and meaningful.
The software is standalone (not a web-tool) and it is completed by perl scripts, facilitating data
management.
The manuscript declare that “Veridical and its associated software programs are available at:
www.veridical.org”.
Actually, Veridical is commercially available to the scientific community. A trial version lasting 30 days can
be downloaded by the website, but in order to obtain binaries, the website requests a registration with an
institutional email address - they reserve the right to deny access to users who register with third-party
mail servers (Gmail, Yahoo, Hotmail, etc.).
No pricing information is included in the manuscript and, more importantly, in the webpages accessible to
download the software, either before or after registration.
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No pricing information is included in the manuscript and, more importantly, in the webpages accessible to
download the software, either before or after registration.
After downloading the software, I was not able to find R scripts that can be useful to generate some plots,
as indicated in the manuscript.
Saying that, the paper is written in a clear language and it is quite complete.
I propose a few revisions that in my opinion can improve the manuscript readability and clarity.
Introduction
Line 13 (minor): indicate which hereditary disease (colon cancer?).
Methods
2nd Par, Line 5 (minor): “Maximising” is used, but probably the meaning is “increasing” (the number
of).
Figure 1 (major): I feel that the info provided by points C and D is trivial, whilst point A's images,
sentences and legends can be improved. Figure 1 C and D shows simply examples of reads that
are mapped continuously and discontinuously to the reference genome. I think that every potential
user of this type of software known well this concept. On the other hand, regarding A and B (upper
part of the figure) there is not clear correspondence between the text in the legend and the image,
and between the image and the text below (the arch overlap the point A in the figure B, whereas
the text says "reads between A and B").
In general, in many cases in the manuscript, the correspondence between legend and figure can
be improved, by indicating more clearly the points specific sentences in the legend refer to.
Regarding this issue, for instance in Figure 4 I can see indicated neither the “exon 12” nor the “14
reads” mentioned in the legend. Please indicate (using colors, boxes, arrows or overlapping text)
key elements in the figure, and revise all figures using the same criterion.
Page 5 (minor): Consider revising the sentence “Furthermore, this transformation allowed us to
avoid the use of non-parametric testing, which has its own pitfalls regarding assumptions of the
underlying data distribution”, since normally it is assumed that parametric tests ground on
assumptions on data distributions, but non-parametric tests by definition can be used without
information about data distribution.
End of the next paragraph (major): “It is important to realize, therefore, that the p-values given by
Veridical are much more robust when the program is provided with a large number of samples.”
This is a pretty clear concept. Please, indicate a general rule to the user/reader: How many
samples are required? Setting a reasonable minimum can be more useful for experimental design
than saying the larger the sample size the most robust the result.
Results
I have two important criticisms about the Results section:

1. The section is not organized in paragraphs, and mixes performance info (run time using different
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1. The section is not organized in paragraphs, and mixes performance info (run time using different
number of samples and variants) with example results.
2. Not clearly saying how these results were obtained. This is important to guarantee repeatability.
(Major) I propose to reorganize the results (considering skipping less important examples; retain
surely Fig. 4 and 6) and insert a first paragraph providing information about the dataset used for
variants validation (how many samples, how many controls) and about the variant calling (BAM
files can be obtained with different settings and criteria and the same apply to calling and filtering of
variants). Moreover, please explain how RNA-seq data are treated, and particularly how they are
normalized to guarantee cross-samples comparability.
(Major) Also, a brief discussion about the impact of disease samples not carrying the given
mutation can be useful, as well as regarding the possibility that a tumour sample not carrying the
considered variant can present altered transcriptome since other variants (or factors) impact on the
“molecular phenotype”.
Figure 4 (minor): Please comment about the possible existence of intronic transcripts (totally
unknown or also annotated in Ensemble, but not displayed in the more conservative RefSeq
annotations).
Figure 5 (minor): Please define better the measure “Read−Abundance Total Intron Inclusion”.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Competing Interests: No competing interests were disclosed.
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